Organization | Cancer Research Campaign

Cancer Research Campaign Report issue

Academic/Hospital Phase 3

Founded: London United Kingdom (1923)

Organization Overview

First Clinical Trial

1992

NCT00002576

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2009

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (22)

bacille calmette-guerin (1 trial)

capecitabine (xeloda) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

doxorubicin (Doxil) (2 trials)

epirubicin (ellence) (2 trials)

exemestane (aromasin) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

goserelin (zoladex) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

leuprolide (lupron) (1 trial)

levofloxacin (levaquin) (1 trial)

mitomycin (mutamycin) (1 trial)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (1 trial)

paclitaxel (taxol) (1 trial)

prednisone (meticorten) (1 trial)

rofecoxib (Vioxx) (1 trial)

tamoxifen (nolvadex) (2 trials)

temsirolimus (torisel) (1 trial)

vincristine (oncovin) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (1)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bile Duct Neoplasms (Phase 3)

Biliary Tract Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Central Nervous System Neoplasms (Phase 3)

Cholangiocarcinoma (Phase 3)

Colorectal Neoplasms (Phase 3)

Fever (Phase 3)

Gallbladder Neoplasms (Phase 3)

Infections (Phase 3)

Intestinal Neoplasms (Phase 3)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Nervous System Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 23